P1/2, N=208, Recruiting, Obsidian Therapeutics, Inc. | N=52 --> 208

P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=60, Not yet recruiting, M.D. Anderson Cancer Center

Here, we report the successful generation and expansion of TIL engineered with regulatable, membrane-bound IL15 (cytoTIL15™ cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2...Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

P1, N=6, Active, not recruiting, Century Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=48 --> 6

P1, N=21, Recruiting, Seattle Children's Hospital | Not yet recruiting --> Recruiting

P1, N=28, Terminated, Century Therapeutics, Inc. | Trial completion date: Aug 2027 --> Jul 2025 | Active, not recruiting --> Terminated; Strategic decision

P2, N=42, Completed, Genome & Company | Active, not recruiting --> Completed

P2, N=10, Terminated, Genome & Company | Recruiting --> Terminated | N=148 --> 10; Sponsor decision

P1, N=30, Not yet recruiting, Shanghai Virogin Biotech Co., Ltd.

P1/2, N=96, Recruiting, Nkarta, Inc. | Phase classification: P1 --> P1/2 | N=48 --> 96

P1, N=21, Not yet recruiting, Seattle Children's Hospital